Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2021
G1 Therapeutics granted new technology add-on payment for Cosela (trilaciclib) by CMS
4 August 2021 - G1 Therapeutics today announced that CMS has granted a new technology add-on payment for Cosela (trilaciclib ...
Posted by Michael Wonder on 21 Jul 2021
Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage
21 July 2021 - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a ...
Posted by Michael Wonder on 19 Jul 2021
CMS proposes rule to increase price transparency, access to care, safety & health equity
19 July 2021 - The Centers for Medicare & Medicaid Services is proposing actions to address the health equity gap, ...
Posted by Michael Wonder on 19 Jul 2021
Will CMS find aducanumab reasonable and necessary for Alzheimer disease after FDA approval?
19 July 2021 - The recent US FDA approval of aducanumab for the treatment of Alzheimer disease triggered both praise and ...
Posted by Michael Wonder on 12 Jul 2021
CMS opens national coverage determination analysis on treatment for Alzheimer’s disease
12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a ...
Posted by Michael Wonder on 07 Jul 2021
Sanders, progressives face split with centrists over plan to cut drug prices in Medicare
7 July 2021 - Those seeking bipartisan measure say empowering Medicare to negotiate for lower prices could hurt innovation. ...
Posted by Michael Wonder on 06 Jul 2021
Costco could have saved Medicare $2.6 billion in drug spending, analysis shows
6 July 2021 - Medicare spent billions more money on generic drugs for its beneficiaries than warehouse chain Costco did ...
Posted by Michael Wonder on 04 Jul 2021
Medicare ‘coverage with evidence development’ for aducanumab? How might it work?
30 June 2021 - In the wake of the FDA’s controversial decision to approve aducanumab for Alzheimer’s disease, how will, and ...
Posted by Michael Wonder on 01 Jul 2021
Guaranteeing Medicare
1 July 2021 - The Australian Government is investing record funding in Medicare, providing more support to Australians as we face ...
Posted by Michael Wonder on 30 Jun 2021
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
28 June 2021 - The FDA’s decision to grant wide-ranging approval to the controversial, pricey new Alzheimer’s drug Aduhelm will ...
Posted by Michael Wonder on 29 Jun 2021
Costly new Alzheimer’s drug could force Medicare to restrict access
28 June 2021 - The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 ...
Posted by Michael Wonder on 27 Jun 2021
Overcharging doctors exposed under Medical Cost Finder revamp
28 June 2021 - A new government website will expose Australian doctors who are overcharging their patients and reveal the stingiest ...
Posted by Michael Wonder on 20 Jun 2021
Expensive brain cancer drug no longer an option under Medicare
19 June 2021 - Brain tumour experts and patient advocates are among those decrying a decision by the seller of ...
Posted by Michael Wonder on 16 Jun 2021
Medicare must study unproven, expensive Alzheimer’s drug
15 June 2021 - Tax payers and patients cannot afford to pay a high price for a treatment not known to ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...